<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05009745</url>
  </required_header>
  <id_info>
    <org_study_id>236067</org_study_id>
    <nct_id>NCT05009745</nct_id>
  </id_info>
  <brief_title>Preimplantation Genetic Screening in IVF Treatment</brief_title>
  <acronym>PGSINIVF</acronym>
  <official_title>Preimplantation Genetic Testing for Aneuploidy (PGT-A) in in Vitro Fertilisation (IVF) Treatment: Pilot Phase of a Randomised Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>King's College London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Guy's and St Thomas' NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>King's College London</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is the pilot phase of a randomised controlled trial.&#xD;
&#xD;
      The purpose of the pilot study is to assess the ability to recruit, randomise, adherence to&#xD;
      the study protocol and plan for a full study.&#xD;
&#xD;
      The purpose of the full study will be to determine if a policy of embryo selection and&#xD;
      transfer based on morphological evaluation and preimplantation genetic testing for aneuploidy&#xD;
      (PGT-A) is a more clinically effective, safer, cost-effective and acceptable way to provide&#xD;
      in vitro fertilisation (IVF) treatment in women of advanced reproductive age compared to the&#xD;
      routine practice of embryo selection and transfer based on morphological evaluation alone.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The target population for the trial are women aged 35 - 42 years undergoing IVF±ICSI&#xD;
      treatment.&#xD;
&#xD;
      Intervention The experimental strategy will be to perform PGT-A (also referred as&#xD;
      preimplantation genetic screening - PGS) involving trophectoderm biopsy on embryos reaching&#xD;
      the blastocyst stage on day 5/6/7 following egg collection. All embryos will be frozen after&#xD;
      the biopsy procedure.&#xD;
&#xD;
      Comprehensive chromosome screening (CCS) of all chromosomes will be performed using next&#xD;
      generation sequencing (NGS). Embryos will be categorised as euploid, mosaic euploid and&#xD;
      aneuploid embryos and embryos will be ranked based on the degree of euploidy.&#xD;
&#xD;
      Only euploid embryos or mosaic euploid embryos deemed suitable to be replaced will be&#xD;
      transferred in subsequent frozen-thawed embryo transfer cycles.&#xD;
&#xD;
      Comparison Women in the control arm will have the fresh embryo transfer procedure on day 5&#xD;
      following egg collection or a frozen-thawed embryo transfer as first line if clinically&#xD;
      indicated in keeping with current routine practice. Embryo selection for transfer will be&#xD;
      based on morphological criteria alone.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 10, 2021</start_date>
  <completion_date type="Anticipated">February 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Pilot phase of a prospective, allocation concealed two arm parallel RCT</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>The participants, care providers, investigators and outcome assessors will not be masked.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Recruitment rate</measure>
    <time_frame>18 months</time_frame>
    <description>Pilot phase RCT with an aim to progress to a multi-centre RCT</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical pregnancy rate</measure>
    <time_frame>21 months</time_frame>
    <description>Clinical pregnancy is defined as presence of an intrauterine gestational sac with a foetal pole and heart beat identified by ultrasound scan.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The intervention will be PGT-A strategy involving trophectoderm biopsy and comprehensive chromosome screening (CCS) using Next Generation Sequencing (NGS). All embryos will be frozen after the biopsy procedure and transferred in a subsequent frozen-thawed embryo transfer. Embryo selection for transfer will be based on morphological criteria and the genetic screening result.&#xD;
Only euploid embryos or mosaic euploid embryos deemed suitable to be transferred will be replaced into the uterus in a subsequent frozen-thawed embryo transfer cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control arm</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Women in the control arm will have the fresh embryo transfer procedure on day 5 following egg collection, or a frozen-thawed embryo transfer as first line over a fresh embryo transfer, if clinically indicated. Embryo selection for transfer will be based on morphological criteria.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>PGT-A Strategy</intervention_name>
    <description>PGT-A strategy involves trophectoderm biopsy, comprehensive chromosome screening (CCS) using Next Generation Screening (NGS), freezing of embryos and replacement in a frozen-thawed embryo transfer cycle.</description>
    <arm_group_label>Intervention</arm_group_label>
    <other_name>PGS Strategy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Inclusion criteria for the study would be women aged 35 - 42 years undergoing IVF ±&#xD;
             ICSI for treatment of infertility&#xD;
&#xD;
          -  Patients with 3 or more good quality embryos (assessed according to the embryo scoring&#xD;
             system of the Association of Clinical Embryologists, UK) on day 3 following egg&#xD;
             collection&#xD;
&#xD;
          -  Ability to provide informed written consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women undergoing preimplantation genetic testing for inherited genetic disorders&#xD;
&#xD;
          -  Gamete donation cycles&#xD;
&#xD;
          -  Untreated hydrosalpinges&#xD;
&#xD;
          -  Untreated uterine pathology (eg: endometrial polyps, submucous fibroids, intramural&#xD;
             fibroids &gt; 5 centimetres in maximum diameter, intrauterine adhesions, uterine septa)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>42 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sesh K Sunkara, MD, FRCOG</last_name>
    <role>Principal Investigator</role>
    <affiliation>King's College London</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ippokratis Sarris, MD, MRCOG</last_name>
    <role>Principal Investigator</role>
    <affiliation>King's Fertility, London</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sponsor Representative</last_name>
    <phone>+44 2071889811</phone>
    <email>R&amp;D@gstt.nhs.uk</email>
  </overall_contact>
  <location>
    <facility>
      <name>King's Fertility</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sesh K Sunkara</last_name>
      <email>sesh.sunkara@kcl.ac.uk</email>
    </contact>
    <contact_backup>
      <last_name>Ippokratis Sarris</last_name>
      <email>ippokratis.sarris@kingsfertility.co.uk</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>October 28, 2020</study_first_submitted>
  <study_first_submitted_qc>August 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 17, 2021</study_first_posted>
  <last_update_submitted>August 12, 2021</last_update_submitted>
  <last_update_submitted_qc>August 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Preimplantation Genetic Testing</keyword>
  <keyword>IVF</keyword>
  <keyword>RCT</keyword>
  <keyword>Pilot Study</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>If there was to be an individual participant data (IPD) meta-analysis on this topic or similar collaboration with other researchers in future, we will share IPD with other researchers.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

